Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20418229rdf:typepubmed:Citationlld:pubmed
pubmed-article:20418229lifeskim:mentionsumls-concept:C0040128lld:lifeskim
pubmed-article:20418229lifeskim:mentionsumls-concept:C0237881lld:lifeskim
pubmed-article:20418229lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:20418229lifeskim:mentionsumls-concept:C0750502lld:lifeskim
pubmed-article:20418229pubmed:issue5lld:pubmed
pubmed-article:20418229pubmed:dateCreated2010-4-26lld:pubmed
pubmed-article:20418229pubmed:abstractTextSubclinical thyroid diseases are defined by abnormal serum thyroid stimulating hormone (TSH) levels associated with normal thyroid hormone concentrations. The diagnosis of these conditions depends on defining the 'normal' euthyroid TSH range; in this review, arguments for and against lowering the upper limit of TSH are summarised. Although, subclinical hypothyroidism and subclinical hyperthyroidism are frequently encountered, their long-term consequences are debated due to conflicting results from many observational studies. The causes, effects and outcomes of treatment of both subclinical diseases are described, and the direction of future research in these conditions is outlined.lld:pubmed
pubmed-article:20418229pubmed:languageenglld:pubmed
pubmed-article:20418229pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20418229pubmed:citationSubsetAIMlld:pubmed
pubmed-article:20418229pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20418229pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20418229pubmed:statusMEDLINElld:pubmed
pubmed-article:20418229pubmed:monthMaylld:pubmed
pubmed-article:20418229pubmed:issn1472-4146lld:pubmed
pubmed-article:20418229pubmed:authorpubmed-author:PearceSimon...lld:pubmed
pubmed-article:20418229pubmed:authorpubmed-author:WeaverJolanta...lld:pubmed
pubmed-article:20418229pubmed:authorpubmed-author:RazviSalmanSlld:pubmed
pubmed-article:20418229pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20418229pubmed:volume63lld:pubmed
pubmed-article:20418229pubmed:ownerNLMlld:pubmed
pubmed-article:20418229pubmed:authorsCompleteYlld:pubmed
pubmed-article:20418229pubmed:pagination379-86lld:pubmed
pubmed-article:20418229pubmed:meshHeadingpubmed-meshheading:20418229...lld:pubmed
pubmed-article:20418229pubmed:meshHeadingpubmed-meshheading:20418229...lld:pubmed
pubmed-article:20418229pubmed:meshHeadingpubmed-meshheading:20418229...lld:pubmed
pubmed-article:20418229pubmed:meshHeadingpubmed-meshheading:20418229...lld:pubmed
pubmed-article:20418229pubmed:meshHeadingpubmed-meshheading:20418229...lld:pubmed
pubmed-article:20418229pubmed:meshHeadingpubmed-meshheading:20418229...lld:pubmed
pubmed-article:20418229pubmed:meshHeadingpubmed-meshheading:20418229...lld:pubmed
pubmed-article:20418229pubmed:year2010lld:pubmed
pubmed-article:20418229pubmed:articleTitleSubclinical thyroid disorders: significance and clinical impact.lld:pubmed
pubmed-article:20418229pubmed:affiliationDepartment of Endocrinology, Gateshead Health NHS Foundation Trust, Gateshead, UK. salman.razvi@ghnt.nhs.uklld:pubmed
pubmed-article:20418229pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20418229pubmed:publicationTypeReviewlld:pubmed